ReviewMedical oncology (Northwood, London, England)2024
Incidence of lymphedema related to various cancers.
Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A pragmatic evaluation of community-based lymphoedema services for individuals at risk of, or living with, cancer-related lymphoedema.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Angiosarcoma Presenting as a Chronic Non-Healing Lower Extremity Ulcer in Lymphoedema: A Challenge.International wound journal · 2026Article
- GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.Microcirculation (New York, N.Y. : 1994) · 2026Article
- Improvement in chronic lymphedema in a gynecologic cancer survivor after starting GLP-1 receptor agonist therapy: A case report.Gynecologic oncology reports · 2026Article
- Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Clinician Perspectives on Implementing Breast Cancer-Related Lymphedema Prospective Screening.JAMA network open · 2026Article
- Axillary Reverse Mapping Improves Quality of Life by Significantly Reducing Clinically Relevant Lymphedema After Axillary Lymph Node Dissection in Older Women with Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Lymphedema: current treatment strategies and future directions in tissue engineering.Frontiers in medicine · 2026Review
- Effects of resistance exercise on reducing the risk of lower-limb lymphedema after gynecological cancer surgery.Asia-Pacific journal of oncology nursing · 2025Article
- Advancing Lymphedema Surveillance With Evidence-Based Practices.Clinical journal of oncology nursing · 2025Review
- [Application efficacy of lymph pads in complete decongestive therapy after lymphatico-venous anastomosis combined with liposuction in patients with lower limb lymphedema].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2025Article
- Lymphoedema Development Following a Cancer Diagnosis: An Anonymised Data Linkage Study in Wales, United Kingdom.International wound journal · 2025Observational
- Prevalence of lymphedema symptoms across cancer diagnoses and association with depression, pain interference and health-related quality of life.Acta oncologica (Stockholm, Sweden) · 2025Article
- Grape seed proanthocyanidins improve lymphatic drainage and blood perfusion in secondary lymphedema models.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related lymphedema (CRL) lacks internationally accepted definition and diagnostic criteria. The accurate incidence of CRL is therefore a challenge and the condition is likely underreported. Patients treated for cancer can develop CRL as a result of surgery, chemotherapy, and/or radiotherapy, which can lead to considerable psychosocial and physical morbidity, and decreased quality of life. Determining CRL incidence is crucial to inform care access and resource allocation, to best support patients affected by this lifelong condition. This review aimed to provide the latest CRL incidence estimates. Using four core databases (MEDLINE, Embase, Web of Science Core Collection, Cochrane Library), a literature search was performed to capture publications dated between 2015 and 2023. A total of 48 articles (33 prospective studies, 15 systematic reviews) met inclusion criteria, providing a sample size of 234,079 cancer patients. Findings revealed CRL incidence across cancer types varied, reported 2-74% in breast, 8-45% in gynecological and urological, 71-90% in head and neck and 2-29% in melanoma cancers. CRL incidence varied between 3 and 21% in preventative lymphedema surgery patients. Projected increases in cancer incidence and improved survival rates are expected to further escalate CRL incidence. Healthcare systems and professionals alike must therefore prepare to meet the growing needs of CRL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.